SCHEMBL465428

SCHEMBL465428

CCCCN(c1nc(NCCCNCCN(CCCN(c2nc(N(CCCC)C3CC(C)(C)N(C)C(C)(C)C3)nc(N(CCCC)C3CC(C)(C)N(C)C(C)(C)C3)n2)c2nc(N(CCCC)C3CC(C)(C)N(C)C(C)(C)C3)nc(N(CCCC)C3CC(C)(C)N(C)C(C)(C)C3)n2)c2nc(N(CCCC)C3CC(C)(C)N(C)C(C)(C)C3)nc(N(CCCC)C3CC(C)(C)N(C)C(C)(C)C3)n2)nc(N(CCCC)C2CC(C)(C)N(C)C(C)(C)C2)n1)C1CC(C)(C)N(C)C(C)(C)C1

nearest known ligand 0.32

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.32
FLT3 P36888 1/20 0.31
TYRO3 Q06418 1/20 0.31
MERTK Q12866 1/20 0.31
GAS6 Q14393 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL88290 0.97 SMN1; SMN2 (0.32) SMN1; SMN2FLT3TYRO3MERTKGAS6
SCHEMBL697310 0.95 SMN1; SMN2 (0.33) SMN1; SMN2FLT3TYRO3MERTKGAS6
SCHEMBL39027 0.88 SMN1; SMN2 (0.35) SMN1; SMN2FLT3TYRO3MERTKGAS6
SCHEMBL9917170 0.87 SMN1; SMN2 (0.39) SMN1; SMN2FLT3TYRO3MERTKGAS6
SCHEMBL471154 0.87 FLT3 (0.37) SMN1; SMN2FLT3TYRO3MERTKGAS6
SCHEMBL9917154 0.85 CRHR1 (0.34) SMN1; SMN2FLT3TYRO3MERTKGAS6
SCHEMBL5484962 0.85 SLC29A1 (0.30)
SCHEMBL13531453 0.85 FLT3 (0.39) SMN1; SMN2FLT3TYRO3MERTKGAS6
SCHEMBL6927282 0.85 SMN1; SMN2 (0.33) SMN1; SMN2FLT3TYRO3MERTKGAS6
SCHEMBL9373111 0.84 FLT3 (0.38) SMN1; SMN2FLT3TYRO3MERTKGAS6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3050919-A1 MIXTURES CONTAINING LIGNOCELLULOSIC MATERIALS WITH SALTS OF N-SUBSTITUTED CARBAMIC ACIDS BASF SE (DE) 2016-08-03 EP disclosed
US-20160215124-A1 THERMOPLASTIC RESIN COMPOSITION, RESIN MOLDED ARTICLE, AND METHOD FOR MANUFACTURING THE RESIN MOLDED ARTICLE WITH PLATING LAYER MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) 2016-07-28 US disclosed
US-9340711-B2 Image display sealant dam composition and image display having the same MOMENTIVE PERFORMANCE MATERIALS JAPAN LLC (JP) 2016-05-17 US disclosed
US-9328228-B2 Chloroprene rubber composition and adhesive composition using said chloroprene rubber composition DENKA COMPANY LIMITED (JP) 2016-05-03 US disclosed
US-20160017130-A1 CHLOROPRENE RUBBER COMPOSITION AND ADHESIVE COMPOSITION USING SAID CHLOROPRENE RUBBER COMPOSITION DENKA COMPANY LIMITED (JP) 2016-01-21 US disclosed
US-20150218427-A1 IMAGE DISPLAY SEALANT DAM COMPOSITION AND IMAGE DISPLAY HAVING THE SAME MOMENTIVE PERFORMANCE MATERIALS JAPAN LLC (JP) 2015-08-06 US disclosed
US-8933161-B2 Thermoplastic resin composition, resin molded article, and method of manufacturing resin molded article with plated layer MITSUBISHI CHEMICAL EUROPE GMBH (DE) 2015-01-13 US disclosed
US-20140002311-A1 THERMOPLASTIC RESIN COMPOSITION, RESIN MOLDED ARTICLE, AND METHOD OF MANUFACTURING RESIN MOLDED ARTICLE WITH PLATED LAYER MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) 2014-01-02 US disclosed
US-20120157564-A1 ENERGY RAY-CURABLE ELASTOMER COMPOSITION BRIDGESTONE CORPORATION (JP) 2012-06-21 US disclosed
WO-2012026786-A3 DISPLACEMENT DESORPTION PROCESS FOR LIGHT OLEFIN SEPARATION KOREA INSTITUTE OF ENERGY RESEARCH (KR) 2012-05-10 WO disclosed
EP-2050772-B1 CURABLE RESIN AND CURABLE COMPOSITION MITSUI CHEMICALS INC (JP) 2011-11-30 EP disclosed
US-20100104879-A1 CLEAR HARD COAT FILM, ANTI-REFLECTION FILM, POLARIZING PLATE AND DISPLAY DEVICE EMPLOYING THE SAME KONICA MINOLTA OPTO, INC. (JP) 2010-04-29 US disclosed
US-20100036050-A1 CURABLE RESIN AND CURABLE COMPOSITION CEMEDINE CO., LTD. (JP) 2010-02-11 US disclosed
EP-2050772-A1 CURABLE RESIN AND CURABLE COMPOSITION Mitsui Chemicals Polyurethanes, Inc. (JP) 2009-04-22 EP disclosed
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof C3AR1, C5, C5AR1 SMN1; SMN2 2273/4885FLT3 1026/4885TYRO3 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.